Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | CCR8 | P51685 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5200914 | 0.82 | TGFBR1 (0.36) | TGFBR1CYP2A6METAP2 | |
| SCHEMBL7100715 | 0.82 | METAP2 (0.40) | TGFBR1CYP2A6METAP2CCR1CCR8 | |
| SCHEMBL28758711 | 0.81 | TGFBR1 (0.45) | TGFBR1CYP2A6METAP2CCR1CCR8 | |
| SCHEMBL5201166 | 0.79 | TGFBR1 (0.48) | TGFBR1MAPK14 | |
| SCHEMBL27648484 | 0.78 | TGFBR1 (0.52) | TGFBR1CYP2A6METAP2CCR1CCR8 | |
| SCHEMBL5200287 | 0.78 | MEN1 (0.40) | TGFBR1CYP2A6METAP2CCR1CCR8 | |
| SCHEMBL19806325 | 0.75 | TGFBR1 (0.68) | TGFBR1MAPK14 | |
| SCHEMBL2047167 | 0.74 | TGFBR1 (0.41) | TGFBR1CYP2A6MAPK14 | |
| SCHEMBL411345 | 0.74 | CYP2A6 (0.35) | TGFBR1CYP2A6METAP2CCR1CCR8 | |
| SCHEMBL5492614 | 0.74 | TGFBR1 (0.58) | TGFBR1METAP2CCR1CCR8MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| US-20060264440-A1 | Pyrazoles and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2006-11-23 | — | — | US | claimed |
| EP-1596656-A4 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC (US) | 2006-10-18 | — | — | EP | claimed |
| JP-2006517592-A | — | — | 2006-07-27 | — | — | JP | claimed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | claimed |
| EP-1596656-A2 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2005-11-23 | — | — | EP | claimed |
| WO-2004072033-A2 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2004-08-26 | — | — | WO | claimed |
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264440-A1 | Pyrazoles and methods of making and using the same | ALK, ACVR1, ALKBH5 | TGFBR1 26/4885CYP2A6 800/4885METAP2 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.